900P - Interim results of fight-201, a phase II, open-label, multicenter study of INCB054828 in patients (pts) with metastatic or surgically unresectable urothelial carcinoma (UC) harboring fibroblast growth factor (FGF)/FGF receptor (FGFR) genetic alterations (GA)

A Necchi,D Pouessel,R Leibowitz-Amit,A Flechon,S Gupta,P Barthelemy,M Maio,X Zhu,E Asatiani,G Serbest,H Zhen,Y Loriot

doi:10.1093/annonc/mdy283.109

900P - Interim results of fight-201, a phase II, open-label, multicenter study of INCB054828 in patients (pts) with metastatic or surgically unresectable urothelial carcinoma (UC) harboring fibroblast growth factor (FGF)/FGF receptor (FGFR) genetic alterations (GA)

A Necchi, D Pouessel + Show 10 more

Open Access

https://doi.org/10.1093/annonc/mdy283.109

Copy DOI

Journal: Annals of oncology : official journal of the European Society for Medical Oncology	Publication Date: Oct 1, 2018
Citations: 37	License type: publisher-specific-oa

Affiliation: Fondazione IRCCS Istituto Nazionale dei Tumori, Institut Claudius Regaud, Sheba Medical Center, Huntsman Cancer Institute, Ospedale Santa Maria alle Scotte, Northwell Health, Incyte (United States), Institut Gustave Roussy

#Unresectable Urothelial Carcinoma #Fibroblast Growth Factor Receptor + Show 6 more

Abstract
Full-Text PDF
Similar Papers

Abstract

900P - Interim results of fight-201, a phase II, open-label, multicenter study of INCB054828 in patients (pts) with metastatic or surgically unresectable urothelial carcinoma (UC) harboring fibroblast growth factor (FGF)/FGF receptor (FGFR) genetic alterations (GA)

Full Text